Featured, Top 1

Spruce Biosciences Soars With BTD For MPS IIIB Therapy TA-ERT

Recently, Spruce Biosciences announced that the FDA had granted its lead therapy, tralesinidase alfa enzyme replacement therapy (TA-ERT) Breakthrough Therapy

Terry Chrisomalis

October 7, 2025

Spruce Biosciences Soars With BTD For MPS IIIB Therapy TA-ERT

MoonLake Posts Mixed Data For Sonelokimab For Patients With Hidradenitis Suppurativa

Positive 3-Year AMT-130 Data For Huntington’s From uniQure Bodes Well For Pre-BLA Meeting

Pfizer Acquires Metsera For $7.3 Billion For Differentiated Weight Loss Drug

Kairos Posts Positive Interim Prostate Cancer Treatment Resistance Data With ENV105

Latest news

Spruce Biosciences Soars With BTD For MPS IIIB Therapy TA-ERT

MoonLake Posts Mixed Data For Sonelokimab For Patients With Hidradenitis Suppurativa

Positive 3-Year AMT-130 Data For Huntington’s From uniQure Bodes Well For Pre-BLA Meeting

Pfizer Acquires Metsera For $7.3 Billion For Differentiated Weight Loss Drug

Top editors picks!

Spruce Biosciences Soars With BTD For MPS IIIB Therapy TA-ERT

1

MoonLake Posts Mixed Data For Sonelokimab For Patients With Hidradenitis Suppurativa

2

Positive 3-Year AMT-130 Data For Huntington’s From uniQure Bodes Well For Pre-BLA Meeting

3

Pfizer Acquires Metsera For $7.3 Billion For Differentiated Weight Loss Drug

4

Other articles

Rapport’s Positive Seizure Data With RAP-219 Could Lead To Phase 3 Program Initiation

Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

One Patient Death Due To Kidney Injury In CytomX’s Ongoing Development Of CX-2051

ORIC Reduces Workforce by 20% But Set To Tackle Two Late-Stage Programs In 2026

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Join Newsletter Today!